Avalo Therapeutics Inc (AVTX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $448.71M
Last updated: Nov 17, 2026 at 11:04 AM ET
Avalo Therapeutics Inc (AVTX) Stock Forecast
Analysts expect Avalo Therapeutics (AVTX) to earn -$2.35 per share in the fiscal year ending Dec 31, 2026. Of 14 analysts, 12 rate the stock Buy or Strong Buy, 2 Hold and 0 Sell or Strong Sell, for a consensus of Buy. For the fiscal year ending Dec 31, 2027, the EPS consensus is -$2.62.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 14 ratings average 2.00, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 86% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 2 | 14.3% |
| Buy | 10 | 71.4% |
| Hold | 2 | 14.3% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 14
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a larger loss.
- Fiscal year ending Dec 31, 2026
- -$2.35
- EPS consensus
- Fiscal year ending Dec 31, 2027
- -$2.62
- EPS consensus
- Next report
- Mar 22, 2027
- Estimated
EPS range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts |
|---|---|---|---|
| Dec 31, 2026 | -$2.35 | -$2.82 to -$1.96 | 8 |
| Dec 31, 2027 | -$2.62 | -$4.10 to -$2.03 | 10 |
Quarterly Estimates
The EPS consensus falls from -$0.52 for the quarter ending Dec 31, 2026 to -$0.62 for the quarter ending Mar 31, 2027.
EPS range
| Quarter ending | EPS consensus | EPS range | EPS analysts |
|---|---|---|---|
| Dec 31, 2026 | -$0.52 | -$0.69 to -$0.40 | 14 |
| Mar 31, 2027 | -$0.62 | -$0.74 to -$0.54 | 4 |
Estimate Revisions
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Quarter ending Mar 31, 2027 | 0 | 1 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$2.61.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$2.35 | -$2.72 | -$2.73 | -$2.72 | -$2.61 | N/A |
| Fiscal year ending Dec 31, 2027 | -$2.62 | -$2.78 | -$2.71 | -$2.74 | -$2.63 | N/A |
| Quarter ending Mar 31, 2027 | -$0.62 | -$0.62 | -$0.62 | -$0.63 | -$0.55 | N/A |
Frequently Asked Questions About AVTX
What is the AVTX stock forecast?
Consensus analyst estimates put Avalo Therapeutics's EPS at -$2.35 for the fiscal year ending Dec 31, 2026. The consensus rating from 14 analysts is Buy.
How do analysts rate AVTX stock?
Of 14 analysts covering Avalo Therapeutics, 2 rate it Strong Buy, 10 Buy, 2 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from AVTX next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$2.35, with estimates from -$2.82 to -$1.96 from 8 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$2.62, with estimates from -$4.10 to -$2.03 from 10 analysts.
How many analysts cover AVTX?
14 analysts rate Avalo Therapeutics stock, and 8 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
AVTX pages: Overview, Earnings, Forecast, Financials, Competitors